GlassScriptPhysician profile
Lesley Roller
NPI 1861093825
$539.39
in general payments reported to CMS, 2019-2025
12 companies · $99.00 in 2025
The $99.00 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.70 · 2022: $99.29 · 2023: $104 · 2024: $152 · 2025: $99.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $180 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $180.41 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $119.97 | 2023-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $78.17 | 2022-2023 | Opdivo |
| Incyte Corporation | $74.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $54.25 | 2023 | Libtayo |
| Lilly USA, LLC | $41.61 | 2021 | |
| Amarin Pharma, INC. | $31.46 | 2021 | |
| Genzyme Corporation | $30.50 | 2024 | |
| Aveo Pharmaceuticals, INC. | $27.83 | 2022 | |
| Genmab U.S., INC. | $26.75 | 2024 | Epkinly |
| Beigene USA, INC. | $21.62 | 2022 | |
| Blueprint Medicines Corporation | $19.61 | 2024 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Roller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.